Exact announced the deal in July. The company now owns 91 percent of Genomic Health, with Genomic Health’s shareholders making up the other 9 percent. Oncotype DX is part of the larger Oncotype IQ Genomic Intelligence Platform, which Exact absorbed. Genomic is no longer listed on the NASDAQ.
Kevin Conroy, chairman and CEO of Exact, said, “We’re excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver advanced tests to providers and patients along their cancer journey.”
More articles on surgery centers:
Former ASC administrator to serve as UNC Health Care’s top admin
Pennsylvania ASC nurse honored for exceptional patient care — 3 details
Sugar Ray Leonard: How to roll with the punches to achieve success
